click below
click below
Normal Size Small Size show me how
Pharm Test #2
| Question | Answer |
|---|---|
| Aripiprazole (atypical antipsychotics) | -Trade name: Abilify -Usual Dosage: 10-30 mg/d -Max Recommend Dose: 30 mg/d |
| Chlorpromazine | -Trade name: Thorazine -Usual Dosage: 100-800 mg/d -Max Recommend Dose: 1000 mg/d |
| Clozapine (atypical antipsychotics) | -Trade name: Clozaril -Usual Dosage: 50-600 mg/d -Max Recommend Dose: 900 mg/d |
| Fluphenazine | -Trade name: Permitil, Prolixin -Usual Dosage: 2-20 mg/d -Max Recommend Dose: 40 mg/d |
| Haloperidol | -Trade name: Haldol -Usual Dosage: 2-20 mg/d -Max Recommend Dose: 100 mg/d |
| Olanzapine (atypical antipsychotics | -Trade name: zyprexa -Usual Dosage: 10-20 mg/d -Max Recommend Dose: 20 mg/d |
| Perphenzine | -trade name: trilafon, triavil -usual dosage: 10-64 mg/d -max recommend dose: 64 mg/d |
| Prochlorperazine | -trade name: comazol, compazine -usual dosage: 15-150 mg/d -max recommend dose: 150 mg/d |
| Quetiapine (atypical antipsychotics) | -trade name: seroquel -usual dosage: 250-600 mg/d -max recommend dose: 800 mg/d |
| Risperidone (atypical antipsychotics) | -trade name: Risperdal -usual dosage: 2-6 mg/d -max recommend dose: 16 mg/d |
| Thioridazine | -trade name: Mellaril -usual dosage: 100-800 mg/d -max recommend dose: 800 mg/d |
| Thiothixene | -trade name: Navane -usual dosage: 4-40 mg/d -max recommend dose: 60 mg/d |
| Triflupromazine | -trade name: Vesprin -usual dosage: 6-150 mg/d -max recommend dose: 150 mg/d |
| Ziprasidone (atypical antipsychotics) | -trade name: Geodon -usual dosage: 40-160 mg/d -max recommend dose: 200 mg/d |
| Simple Partial Seizures | Limited (focal) motor or sensory signs (convulsions confined to 1 limb, specific sensory hallucinations); consciousness remains intact |
| Complex Partial Seizures (needed to differentiate this from absence seizures) | Consciousness impaired; bizarre behavior; wide variety of other manifestations; specific EEG abnormality |
| Partial becoming generalized | symptoms progressively increase until seizure resembles a generalized (tonic-clonic) seizure |
| Absence (petit mal) seizures | sudden, brief loss of consciousness; motor signs may be absent or may range from rapid eye-blinking to symmetrical jerking movements of entire body |
| Myoclonic Seizures | sudden, brief, "shocklike" contractions of muscles in the face and trunk, or in 1 or more extremities; contractions may be single or multiple; consciousness may be impaired |
| Clonic Seizures | Rhythmic, synchronized contractions throughout the body; loss of consciousness |
| Tonic Seizures | Generalized sustained muscle contractions throughout body; loss of consciousness |
| Tonic-clonic (grand mal) seizures | Major convulsions of entire body; sustained contraction of all muscles (tonic phase) followed by powerful rhythmic contractions (clonic phase); loss of consciousness |
| Atonic Seizures | sudden loss of muscle tone in the head and neck, 1 limb, or throughout the entire body; consciousness may be maintained or lost briefly |
| Barbiturates | -Amobarbital (Amytal) -Pentobarbital (Nembutal) -Phenobarbital (Solfoton) -Primidone (Mysoline) -Secobarbital (Seconal) |
| Barbiturates | potentiate inhibitory effects of GABA; may also decrease excitatory effects of glutamate |
| Benzodiazepines | -Clonazepam (Klonopin) -Clorazepate (Tranxene) -Diazepam (Valium) -Lorazepam (Ativan) |
| Benzodiazepines | potentiate inhibitory effects of GABA |
| Carboxylic acids | -Valproic acid (Depakene, Depakote) |
| Carboxylic acids | unclear; may hyperpolarize membrane through an effect on potassium channels; higher concentrations increase CNS GABA concentrations |
| Hydantoins | -Fosphenytoin (Cerebyx) -Phenytoin (Dilantin) |
| Hydantoins/Iminostilbenes | primary effect is to stabilize membrane by blocking sodium channels in repetitive-firing neurons; higher concentrations may also influence concentrations of other neurotransmitters (GABA, norepinephrine) |
| Iminostilbenes | -Carbamazepine (Tegretol) -Oxcarbazepine (Trileptal) |
| Succinimides | -Ethosuximide (Zarontin) |
| Succinimides | affect calcium channels; appear to inhibit spontaneous firing in thalamic neurons by limiting calcium entry |
| Felbamate (Felbatol) | used alone or as an adjunct in partial seizures in adults; treatment adjunct in partial and generalized seizures associated with Lennox-Gastaut syndrome in children |
| Gabapentin (Neurontin) | treatment adjunct in partial seizures in adults and children over age 3 |
| Lamotrigine (Lamictal) | use alone or as a treatment adjunct in partial seizures in adults over age 16; treatment adjunct in generalized seizures associated with Lennox-Gastaut syndrome in adults and children over age 2 |
| Levetiracetam (Keppra) | treatment adjunct in partial onset of seizures in adults |
| Tiagabine (Gabitril) | Treatment adjunct in partial seizures in adults and children over age 12 |
| Topiramate (Topamax) | treatment adjunct in partial onset seizures |
| Zonisamide (Zonegran) | treatment adjunct in partial seizures in adults |
| Levodopa-MOA | resolves dopamine deficiency by being converted to dopamine after crossing blood-brain barrier |
| Levodopa | still the best drug for resolving parkinsonian symptoms; long-term use limited by side effects and decreased efficacy |
| Dopamine Agonists (bromocriptine, cabergoline, pergoline, pramipexole, ropinirole) | MOA: directly stimulates dopamine receptors in basal ganglia |
| Dopamine Agonists (bromocriptine, cabergoline, pergoline, pramipexole, ropinirole) | may produce fewer sides effects (dyskinesias, fluctuations in response) than levodopa; preliminary evidence suggests that early use may also delay the progression of Parkinson disease |
| Anticholinergics-MOA | inhibit excessive acetylcholine influence caused by dopamine deficiency |
| Anticholinergics | Use in Parkinson disease limited by frequent side effects |
| Amantadine-MOA | unclear, may inhibit the effects of excitatory amino acids in the basal ganglia |
| Amantadine | may be used alone during early/mild stages or added to drug regimen when levodopa loses effectiveness |
| Selegiline-MOA | inhibits the enzyme that breaks down dopamine in the basal ganglia; enables dopamine to remain active for longer periods of time |
| Selegiline | may improve symptoms, especially in early stages of Parkinson disease; ability to produce long-term benefits unclear |